Back

A real-world comparison of vernakalant efficacy and safety for pharmacological cardioversion in patients with recent-onset atrial fibrillation in an emergency department and after cardiac surgery.

18 June 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 1 - Atrial Fibrillation - Antiarrhythmic drugs Antiarrhythmic drugs (Atrial Fibrillation) EHRA Premium Access EHRA EUROPACE - CARDIOSTIM 2017

About the speaker

Photo
Doctor Joaquin Osca Asensi

University Hospital La Fe, Valencia (Spain)

6 More presentations in this session

Presentation thumbnail
Vernakalant versus ibutilide for immediate conversion of recent-onset Atrial Fibrillation
Doctor I. Vogiatzis (Veria, GR)
Abstract Slides
Presentation thumbnail
Intravenous antazoline for cardioversion of recent onset atrial fibrillation in patients with stable coronary artery disease.
Professor M. Farkowski (Warsaw, PL)
Abstract Slides
Presentation thumbnail
Impact of gender: rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective study
Presentation thumbnail
Comparison of local activation time annotation algorithms in high density mapping of regular atrial tachycardias
Professor J. De Pooter (Gent, BE)
Abstract
Presentation thumbnail
Higher persistence but lower compliance with direct oral anticoagulants treatment for atrial fibrillation following a personalized therapeutic information: paradoxical results of the MONACO study
Professor J. Davy (Montpellier, FR)
Abstract Slides

Access the full session

Session thumbnail
Poster session 1 - Atrial Fibrillation - Antiarrhythmic drugs

The Event

Event poster

EHRA EUROPACE - CARDIOSTIM 2017

18 June - 21 June 2017

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources